Biogen (BIIB) Projects $222 Million in R&D Expenses for Q4 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- R&D Expense Projection: Biogen anticipates approximately $222 million in R&D expenses for Q4 2025, which is expected to reduce earnings per share by about $1.26, indicating a significant investment decision in research and development.
- Impact of Collaboration Agreements: The expenses are primarily related to collaboration and licensing agreements, including upfront and milestone payments, as well as premiums on equity securities for acquired R&D assets, showcasing the company's ongoing commitment to innovation.
- Stock Price Fluctuation: Following the announcement, Biogen's shares closed at $178.30, down 3.95%, reflecting market concerns regarding future financial performance, which may impact investor confidence.
- Financial Transparency: By disclosing these expenses through an SEC filing, the company demonstrates its commitment to financial transparency, potentially providing future investors with a clearer financial outlook.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 184.00 USD with a low forecast of 149.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
12 Buy
10 Hold
0 Sell
Moderate Buy
Current: 178.300
Low
149.00
Averages
184.00
High
250.00
Current: 178.300
Low
149.00
Averages
184.00
High
250.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
